Worth reading
51Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Who is moving to which position
Resolved 14 May 2026Incoming appointee
2 itemsScheduled Appointment Date24 June 2026 (subject to approval at the 154th Annual General Meeting of Shareholders)
Sugimoto Masashi (杉本 雅史)
Previous positionRepresentative Director and Chairman of 天藤製薬㈱ (currently serving), Executive Adviser to the Rohto Group (scheduled to retire in June 2026), and Management Strategy Adviser to ROHTO PHARMACEUTICAL CO.,LTD. (scheduled to assume the position in July 2026)
New positionOutside directors
生年月日 24 August 1961入社年 1984
Yamahata Hiroshi (山畑 博史)
Previous positionPartner at Miyake Law Office (currently serving), Visiting Professor at Doshisha University Graduate School of Judicial Studies (currently serving), and other positions
New positionOutside director who is an Audit and Supervisory Committee member
生年月日 9 October 1976入社年 Not disclosed
Departing officer
3 itemsDate of departure24 June 2026
Nakagawa Shinji (中川 真二)Next role stated
Former PositionDirector, Assistant to the President
New positionAdviser
Yanase Hideki (柳瀬 英喜)Stepping down
Former PositionOutside directors
New positionNot disclosed
Oda Takaaki (織田 貴昭)Stepping down
Former PositionOutside director who is an Audit and Supervisory Committee member
New positionNot disclosed
“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.
Whether the incumbent will remain in office (whether they will retain their position)
Nakagawa Shinji (中川 真二) will remain with the Company as an Adviser. No information is provided on whether Yanase Hideki (柳瀬 英喜) or Oda Takaaki (織田 貴昭) will remain in their positions.
Directors after the change7Number
Shareholders’ meeting approvalApproval is required. The 154th Annual General Meeting of Shareholders is scheduled to be held on 24 June 2026.
| Item | Details |
|---|---|
| Resolution date | 14 May 2026 |
| Scheduled Appointment Date | 24 June 2026 (subject to approval at the 154th Annual General Meeting of Shareholders) |
| Date of departure | 24 June 2026 |
| Name of appointee | Sugimoto Masashi (杉本 雅史), Yamahata Hiroshi (山畑 博史) |
| Appointee's new position | Outside directors, Outside director who is an Audit and Supervisory Committee member |
| Appointee's previous position | Representative Director and Chairman of 天藤製薬㈱ (currently serving), Executive Adviser to the Rohto Group (scheduled to retire in June 2026), and Management Strategy Adviser to ROHTO PHARMACEUTICAL CO.,LTD. (scheduled to assume the position in July 2026), Partner at Miyake Law Office (currently serving), Visiting Professor at Doshisha University Graduate School of Judicial Studies (currently serving), and other positions |
| Appointee's date of birth | 24 August 1961, 9 October 1976 |
| Year the appointee joined the Company | 1984, Not disclosed |
| Name of departing officer | Nakagawa Shinji (中川 真二), Yanase Hideki (柳瀬 英喜), Oda Takaaki (織田 貴昭) |
| Former position of departing officer | Director, Assistant to the President, Outside directors, Outside director who is an Audit and Supervisory Committee member |
| New position of departing officer | Adviser, Not disclosed, Not disclosed |
| Whether the incumbent will remain in office | Nakagawa Shinji (中川 真二) will remain with the Company as an Adviser. No information is provided on whether Yanase Hideki (柳瀬 英喜) or Oda Takaaki (織田 貴昭) will remain in their positions. |
| Number of directors after the change | 7 (including 4 outside directors) |
| Subject to Approval by the General Meeting of Shareholders | Approval is required. The 154th Annual General Meeting of Shareholders is scheduled to be held on 24 June 2026. |
Items this document does not state (7)
Number of shares held by the appointeeReason for departureReason for changeReasons for appointmentFiling as an independent officerDetails of organizational changesChange in Corporate Governance Structure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company has not provided a specific explanation for the changes.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.